Description

Sermorelin stimulates endogenous growth hormone release, improving body composition, offering anti-aging benefits, and potentially supporting heart health, making it effective for treating growth hormone deficiency and enhancing overall well-being. (PMID: 18031173, PMID: 33468654)

Sermorelin Research Topics:

1. Growth Hormone Stimulation:

   Sermorelin effectively stimulates the production and release of endogenous growth hormone from the pituitary gland, making it useful for treating growth hormone deficiency in both children and adults. (PMID: 18031173)

2. Body Composition:

   Sermorelin has been shown to improve body composition by increasing lean muscle mass and reducing fat, particularly beneficial for hypogonadal males. (PMID: 18031173)

3. Anti-Aging:

   Sermorelin has potential anti-aging benefits, including improved skin thickness, increased lean body mass, and enhanced overall well-being, by reversing age-related decreases in growth hormone and IGF-1 levels. (PMID: 18031173)

4. Heart Health:

   Research suggests that Sermorelin, along with other GHRH agonists, may benefit heart health by potentially treating myocardial infarction and other heart conditions. (PMID: 33468654)

Peer-Reviewed Studies 

• A potentially effective drug for patients with recurrent glioma: sermorelin.

Chang, Y., Huang, R., Zhai, Y., Huang, L., Feng, Y., Wang, D., Chai, R., Zhang, W., & Hu, H. (2021). Annals of translational medicine, 9(5), 406.

• Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress.

Kozlovskaya, M. M., Kozlovskii, I. I., Val’dman, E. A., & Seredenin, S. B. (2003). Neuroscience and Behavioral Physiology, 33(9), 853-860.

Structure

Sequence: Tyr-DL-Ala-DL-Asp-DL-Ala-DL-xille-DL­Phe-DL-xiThr-DL-Asn-DL-Ser-DL-Tyr-DL-Arg-DL­Lys-DL-Val-DL-Leu-Gly-DL-Gln-DL-Leu-DL-Ser-DL­Ala-DL-Arg-DL-Lys-DL-Leu-D L-Leu-DL-Gln-D L-Asp­DL-xi I le-DL-Met-DL-Ser-D L-Arg
Molecular Formula: C149H24sN44042S
Molecular Weight: 3357 .933 g/mol
PubChem CID: 16129620

Sermorelin Peptide Research 

1. Sermorelin and Heart Health

Heart attack, while acutely life-threatening, can also lead to long-term disability secondary to heart failure, cardiac conduction abnormalities (arrhythmias), reduced exercise capacity, pain, and more. A number of these problems result from cardiac remodeling that follows damage to myocytes (heart muscle cells). Often, cardiac remodeling leads not only to scarring in the area of damage following a heart attack but in surrounding, undamaged areas as well. This remodeling causes a number of long-term problems and research has shown that preventing it from happening can significantly improve outcomes both immediately after a heart attack and years down the line.

In 2016, a study in pigs revealed that the Sermorelin administration is effective in reducing the remodeling that follows a heart attack. The research showed that Sermorelin: 

• reduces cell death in cardiomyocytes
• increases the production of extracellular matrix components needed for adequate healing
• increases the growth of blood vessels to damaged tissue and
• reduces the production of substances that cause damaging inflammation

Clinically, Sermorelin’s effects are seen in improved diastolic function, reduced scar size, and increased capillary growth [1],[2]. There is current research exploring the benefits of sermorelin in other forms of heart disease, such as heart failure and even valve disorders. 

GHRH treatment reduces scar mass. A. Shows a graph of the percent change in scar mass over time on top and the relationship between the percent change in scar mass as a percentage of left ventricular mass. B. Shows images of the heart before and after 4 weeks of Sermorlin treatment or placebo. 

2. Sermorelin and Epilepsy

Gamma-aminobutyric acid (GABA) is a central nervous system signaling molecule known to reduce electrical activity in the spinal cord and reduce overall electrical excitability in the central nervous system. A number of anti-seizure medications work either by increasing levels of GABA in the central nervous system or by binding to GABA receptors and mimicking the effects of GABA. In a recent study of mice with epilepsy, scientists administered GHRH analogues, like Sermorelin, to test the effect of these peptides on seizure activity. It turns out that GHRH analogues are effective in suppressing seizures by activating GABA receptors [3]. This is a very new finding and an active area of research as medications for treating seizure conditions, while effective, have a range of detrimental side effects that reduce their clinical use. 

3. Sermorelin and Sleep

There is good evidence that sleep cycles are regulated by orexin, a potent neurochemical produced by certain neurons in the brain. It is also well understood that growth and healing, which are strongly associated with growth hormone secretion, primarily take place during sleep. Research in rainbow trout suggests that this is no coincidence, with an intact GHRH axis being a necessary component for proper orexin secretion and function. In addition, the research reveals that exogenous administration of sermorelin and other GHRH agonists can boost orexin secretion [4]. There is ongoing research into the benefits of using Sermorelin in sleep disorders. 

4. Sermorelin Preferred to Growth Hormone 

Sermorelin is a growth hormone-releasing hormone derivative and, as such, produces all of the same effects that GH produces, including increasing muscle mass, boosting long bone growth, and reducing adipose tissue. Even though the effects are the same, the side effects are not. In fact, sermorelin is the preferred way to increase GH levels in humans, even over the exogenous administration of growth hormone itself. The primary reason for this preference is that Sermorelin is subject to physiological feedback mechanisms that help to prevent common problems encountered with GH administration. These problems include overdose, improper dosing, and unintended side effects like edema, joint pain, and dysregulation of normal physiology [5]. 

A second reason to prefer Sermorelin is that research shows it is not subject to tachyphylaxis, the process by which the body becomes accustomed to medication and requires higher and higher doses to achieve desired effects. In some cases, tachyphylaxis is so severe that a drug holiday (complete cessation of use of a medication) is required to regain the effects of a medication. Long­term use of sermorelin in certain clinical settings as well as animal studies of the peptide indicate that the body has a unique response to the peptide. Rather than down-regulate the production of GHRH receptors with the administration of Sermorelin, the body instead increases their production. This ensures that Sermorelin’s effects are unchanged, that tachyphylaxis does not develop to a substantial degree, and that dose escalation is generally not required [6]. 

Sermorelin exhibits moderate side effects, and low oral and excellent subcutaneous bioavailability in mice. Per kg, dosage in mice does not scale to humans. Sermorelin for sale at Life Link Research is limited to educational and scientific research only, not for human consumption. Only buy Sermorelin if you are a licensed researcher.

Article Author

The above literature was researched, edited, and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Scientific Journal Author 

Richard F. Walker, Ph.D, R.Ph, lead author of A better approach to the management of adult-onset growth hormone insufficiency?”, received a BS in pharmacy from Rutgers University, an MS in Biochemistry from New Mexico State University, and a PhD in physiology from Rutgers University. He holds postdoctoral fellowships in neuroendocrinology and neuropharmacology at Duke University College of Medicine (Center for the Study of Aging and Human Development) and the University of California, Berkeley, respectively. 

Richard F. Walker, Ph.D, R.Ph is being referenced as one of the leading scientists involved in the research and development of Sermorelin. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Life Link Research and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Richard F. Walker, Ph.D, R.Ph is listed in [5] under the referenced citations. 

Referenced Citations 

1. L. L. Bagno et al., “Growth Hormone­- Releasing Hormone Agonists Reduce Myocardial Infarct Scar in Swine With Subacute lschemic Cardiomyopathy,” J. Am. Heart Assoc. Cardiovasc. Cerebrovasc. Dis., vol. 4, no. 4, Mar. 2015.
2. R. M. Kanashiro-Takeuchi et al., “New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor,” Oncotarget, vol. 6, no. 12, pp. 9728-9739, Mar. 2015.
3. S. Tang et al., “Interactions between GHRH and GABAARs in the brains of patients with epilepsy and in animal models of epilepsy,” Sci. Rep., vol. 7, Dec. 2017.
4. B. S. Shepherd et al., “Endocrine and orexigenic actions of growth hormone secretagogues in rainbow trout (Oncorhynchus mykiss),” Comp. Biochem. Physiol. A. Mol. lntegr. Physiol., vol. 146, no. 3, pp. 390-399, Mar. 2007. 
5. R. F. Walker, “Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?,” Clin. lnterv. Aging, vol. 1, no. 4, pp. 307-308, Dec. 2006.
6. S. T. Wahid, P. Marbach, B. Stolz, M. Miller, R. A. James, and S. G. Ball, “Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues,” Eur. J. Endocrinol., vol. 146, no. 3, pp. 295-302, Mar. 2002.